Drug Trial Radar · NCT02750345
Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1)
Last checked: Nov 19, 2026Latest source record: Jun 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Mar 2016
Primary completion
May 2016
Study completion May 2016
Sponsor
- Lead sponsor
- Cycle Pharmaceuticals Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Apr 25, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether Nitisinone 10 mg Tablets (Test Product 1) and Nitisinone 10 mg Tablets 'Baked' for 6 months @ 40°C/75% RH (Test Product 2) are bioequivalent to the reference product Orfadin 10 mg hard capsules.
Conditions
- Hereditary Tyrosinemia, Type I
Interventions
NitisinoneDrug
A single oral dose of Nitisinone 10 mg Tablet will be administered.
Nitisinone Baked TabletDrug
A single oral dose of Nitisinone 10 mg Tablet (6 months @ 40°C/75% RH) will be administered.
OrfadinDrug
A single oral dose of Orfadin 10 mg hard capsule will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax)Time frame: 0 - 120 hours post-dose
- Area Under the Plasma Concentration Versus Time Curve (AUC(0-120))Time frame: 0 - 120 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa)
Bloemfontein, Free State, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.